Mirvaso® Utilization and Patient Satisfaction Study - MUSE
Research type
Research Study
Full title
Mirvaso® Utilization and Patient Satisfaction Study - MUSE
IRAS ID
176981
Contact name
Stéphanie Leclerc
Contact email
Sponsor organisation
Galderma R&D SNC
Duration of Study in the UK
0 years, 7 months, 8 days
Research summary
Rosacea is a common skin disorder characterized by flushing and persistent redness of the skin in the central facial area, with or without the presence of other signs. Rosacea may cause embarrassment, anxiety and low self-esteem among patients.
Although several medications are approved for the treatment of inflammatory lesions of rosacea, Mirvaso® is the first and only topical medication approved for the treatment of rosacea. When applied once-daily topically on the face, the treatment is effective and safe in reducing the severity of rosacea. The main objective of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® is prescribed.
This is a non-interventional study (NIS) which means the medicinal product is prescribed in the usual manner. The assignment of the patient is not decided in advance by a trial protocol but falls within current clinical practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study.
Therefore, NIS with a large sample size can provide essential scientific information on the real-life scenario and can generate more representative data of the general population, in contrast to randomized and controlled trials with smaller sample size and stringent inclusion/exclusion criteria.
REC name
North East - York Research Ethics Committee
REC reference
15/NE/0235
Date of REC Opinion
8 Jul 2015
REC opinion
Further Information Favourable Opinion